GO:0060192 negative regulation of lipase activity: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060192 (negative regulation of lipase activity) is a biological process that decreases the frequency, rate or extent of lipase activity, the hydrolysis of a lipid or phospholipid.
• Lipolysis is tightly controlled by hormonal, nutritional and transcriptional signals, and its dysregulation contributes to obesity, insulin resistance and ectopic fat deposition [1,8].
• Key negative regulators include sphingomyelin in plasma lipoproteins, which inhibits hepatic lipase activity, and PNPLA7, which restrains adipose browning and supports mitophagy.
• Prostaglandin E2 via the EP4 receptor promotes lipolysis and fibrosis in adipose tissue, highlighting the balance between pro- and anti-lipolytic signals.
• Trehalose-induced lysosomal stress activates TFEB and the autophagy-lysosome biogenesis response, illustrating how cellular stress pathways intersect with lipid catabolism.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of candidate negative regulators of lipase activity in metabolic disease research.
Description
GO:0060192, negative regulation of lipase activity, is a biological process that decreases the frequency, rate or extent of lipase activity, defined as the hydrolysis of a lipid or phospholipid. Lipases are enzymes that break down triglycerides and other lipids into free fatty acids and glycerol, and their activity must be precisely tuned to match energy demand and nutrient availability. When this negative regulation fails, excessive lipolysis can flood the circulation with fatty acids, promoting ectopic fat deposition, insulin resistance and metabolic disease [1,8]. Conversely, excessive suppression of lipase activity can impair lipid mobilization and contribute to obesity and hepatic steatosis. Understanding the molecular players that restrain lipase activity is therefore central to metabolic physiology and to the development of therapeutics for cardiometabolic disorders. This article integrates the QuickGO definition of GO:0060192 with verified PubMed literature to describe the mechanisms, key genes, disease links and research methods relevant to this process.
negative regulation of lipase activity At A Glance
| GO ID | GO:0060192 |
|---|---|
| GO term | negative regulation of lipase activity |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the frequency, rate or extent of lipase activity, the hydrolysis of a lipid or phospholipid |
| Biological context | Lipid homeostasis, energy metabolism, adipocyte biology, hepatic lipoprotein metabolism |
| Representative regulators | Sphingomyelin in plasma lipoproteins, PNPLA7, prostaglandin E2-EP4 signaling |
| Disease relevance | Obesity, insulin resistance, ectopic fat deposition, hepatic steatosis, acne metabolomics |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, lipase activity assays, lipidomics, transcriptomics |
What Is GO:0060192?
In simple terms, GO:0060192 describes any cellular process that slows down or stops lipases from breaking down lipids. The official QuickGO definition states: Any process that decreases the frequency, rate or extent of lipase activity, the hydrolysis of a lipid or phospholipid. This includes direct inhibition of lipase enzymes, sequestration of substrates, and signaling events that reduce lipase gene expression or catalytic efficiency [1,4,7].
Why Is negative regulation of lipase activity Important in Cell Biology?
Negative regulation of lipase activity is essential for metabolic homeostasis because unrestrained lipolysis releases excessive free fatty acids that impair insulin signaling and promote ectopic fat deposition [1,8]. Conversely, insufficient lipolysis contributes to lipid storage disorders. This process is therefore a therapeutic target in obesity, type 2 diabetes and fatty liver disease, and it intersects with autophagy-lysosome biology and inflammatory signaling [3,8].
• Controls the rate of triglyceride hydrolysis and free fatty acid release from adipocytes.
• Prevents lipotoxic damage to pancreatic beta cells and other tissues.
• Regulates hepatic lipase activity and lipoprotein remodeling.
• Modulates adipose tissue browning and mitophagy through PNPLA7.
• Links inflammatory prostaglandin signaling to adipose fibrosis and insulin resistance.
• Impacts skin sebum lipids and acne pathogenesis through diet-related metabolomics.
• Involves lysosomal stress responses and TFEB activation.
• Provides targets for anti-obesity and insulin-sensitizing therapeutics [1,8].
• Requires lipase-specific foldases for proper enzyme folding and activity.
• Serves as a model process for studying enzyme regulation by protein-protein and lipid-protein interactions [4,7].
What Happens During negative regulation of lipase activity?
Hormonal and nutritional signals that suppress lipolysis
In simple terms: Insulin and other fed-state signals tell fat cells to stop breaking down fat.
Lipolysis is acutely inhibited by insulin and other anabolic signals that reduce cAMP levels and PKA activity, thereby decreasing phosphorylation and activation of lipases such as ATGL, HSL and MGL. In the fed state, this negative regulation prevents unnecessary fatty acid release. Prostaglandin E2 acting through the EP4 receptor can also modulate adipose lipolysis and fibrosis, showing that inflammatory mediators participate in this regulatory network.
Lipid-protein interactions that inhibit lipase catalysis
In simple terms: Certain lipids in the blood can directly block lipase enzymes.
Sphingomyelin associated with plasma lipoproteins negatively regulates hepatic lipase activity, providing an example of how the lipid environment controls enzyme function. This inhibition is relevant to lipoprotein remodeling and hepatic lipid handling. Lipase-specific foldases also influence lipase folding and secretion, indirectly affecting the pool of active enzyme available for regulation.
Transcriptional and post-transcriptional control of lipase expression
In simple terms: Cells can make less lipase enzyme by turning down its gene or destroying its mRNA.
Negative regulation of lipase activity can occur by reducing lipase gene transcription or by promoting mRNA decay, thereby lowering enzyme abundance. Transcription factors such as TFEB coordinate lysosomal and autophagy-lysosome biogenesis in response to stress, which can indirectly affect lipid catabolism. PNPLA7 is a patatin-like phospholipase that influences adipose tissue mitophagy and browning, illustrating how lipase-family proteins can themselves be regulated to control lipid flux.
Autophagy-lysosome and stress responses
In simple terms: Cellular recycling and stress pathways can put the brakes on fat breakdown.
Trehalose causes low-grade lysosomal stress that activates TFEB and the autophagy-lysosome biogenesis response, a pathway that intersects with lipid droplet turnover and lipase regulation. In pancreatic beta cells, Bax Inhibitor-1 preserves proteostasis by limiting proinsulin misfolding and programmed cell death, a stress-response mechanism that can influence lipid handling and lipase activity indirectly. These examples show that negative regulation of lipase activity is embedded in broader cellular quality-control networks.
Adipose tissue remodeling and fibrosis
In simple terms: Long-term changes in fat tissue can change how much lipase activity is allowed.
Chronic prostaglandin E2-EP4 signaling promotes lipolysis and fibrosis in adipose tissue, leading to ectopic fat deposition and insulin resistance. This indicates that sustained pro-lipolytic signals can overwhelm negative regulatory mechanisms. Understanding these remodeling processes is important for designing interventions that restore balanced lipase activity [1,8].
Key Genes Involved in GO:0060192 negative regulation of lipase activity
The following genes and proteins are experimentally implicated in negative regulation of lipase activity or in closely related lipolytic control pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PNPLA2 (ATGL) | Rate-limiting triglyceride lipase | Target of negative regulation; KO models show impaired lipolysis |
| LIPE (HSL) | Hormone-sensitive lipase | Phosphorylation-dependent regulation by insulin/cAMP |
| MGLL (MGL) | Monoglyceride lipase | Completes lipolysis; regulated by feedback |
| PNPLA7 | Patatin-like phospholipase in adipose tissue | Mediates Parkin-mitochondrial recruitment, inhibits browning |
| LIPC (hepatic lipase) | Lipoprotein remodeling enzyme | Activity inhibited by sphingomyelin in lipoproteins |
| TFEB | Transcription factor for autophagy-lysosome biogenesis | Activated by lysosomal stress; links to lipid catabolism |
| BAX (Bax Inhibitor-1 pathway) | Apoptosis regulator and proteostasis modulator | Preserves beta-cell proteostasis; indirect lipid effects |
| PTGER4 (EP4 receptor) | Prostaglandin E2 receptor | Promotes lipolysis and fibrosis in adipose tissue |
| INSR | Insulin receptor | Mediates insulin-dependent suppression of lipolysis |
| AKT | Insulin signaling kinase | Phosphorylates PDE3B to lower cAMP and inhibit lipolysis |
| PDE3B | Phosphodiesterase | Degrades cAMP to reduce PKA-mediated lipase activation |
| PRKACA (PKA) | Protein kinase A | Phosphorylates HSL and perilipins to stimulate lipolysis |
| PLIN1 (perilipin-1) | Lipid droplet coat protein | Gatekeeper of lipase access to lipid droplets |
| CGI-58 (ABHD5) | ATGL co-activator | Regulated by perilipin phosphorylation |
| G0S2 | ATGL inhibitor | Direct negative regulator of ATGL activity |
| FABP4 | Fatty acid binding protein | Modulates lipid flux and feedback on lipolysis |
| LPL (lipoprotein lipase) | Plasma triglyceride hydrolase | Regulated by apolipoproteins and nutritional state [1,7] |
How Is negative regulation of lipase activity Regulated?
Negative regulation of lipase activity is controlled at multiple levels. Acutely, insulin signaling activates phosphodiesterase PDE3B, lowering cAMP and reducing PKA-dependent phosphorylation of HSL and perilipins, which suppresses lipolysis. Transcriptional control includes TFEB-mediated autophagy-lysosome biogenesis in response to lysosomal stress. Lipid-protein interactions, such as sphingomyelin inhibition of hepatic lipase, provide direct enzymatic restraint. Inflammatory mediators like prostaglandin E2 can shift the balance toward lipolysis and fibrosis, overriding negative regulation. PNPLA7 influences adipose mitophagy and browning, adding another layer of control.
negative regulation of lipase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PNPLA2 (ATGL) | Neutral lipid storage disease, insulin resistance | Knockout and point-mutation adipocyte models |
| LIPC | Dyslipidemia, hepatic steatosis | Hepatocyte knockout and overexpression |
| PNPLA7 | Obesity, adipose browning defects | Adipose-specific knockout and tagged knock-in |
| PTGER4 | Adipose fibrosis, insulin resistance | Knockout and overexpression in adipocytes |
| TFEB | Lysosomal storage and metabolic stress | Knockout and knock-in reporter models |
Obesity and insulin resistance
Dysregulated lipolysis with insufficient negative regulation of lipase activity contributes to elevated circulating free fatty acids, ectopic fat deposition and insulin resistance [1,8]. Prostaglandin E2-EP4 signaling promotes adipose fibrosis and ectopic fat, worsening metabolic dysfunction. Targeting negative regulators of lipase activity may improve insulin sensitivity.
Hepatic steatosis and lipoprotein disorders
Hepatic lipase activity is modulated by sphingomyelin in plasma lipoproteins, and altered regulation can affect lipoprotein remodeling and liver lipid handling. Imbalances in hepatic lipase activity are linked to dyslipidemia and fatty liver disease [1,4].
Beta-cell stress and diabetes
Bax Inhibitor-1 preserves pancreatic beta-cell proteostasis by limiting proinsulin misfolding and programmed cell death, a stress-response pathway that can influence lipid handling and lipase activity indirectly. Lipotoxic stress from unrestrained lipolysis can impair beta-cell function [1,5].
Acne and skin lipid metabolism
Diet-related metabolomics and inflammation influence sebum lipid composition and comedogenesis in acne, processes that involve lipase-mediated lipid hydrolysis in the skin. Negative regulation of lipase activity may therefore have dermatological relevance.
From negative regulation of lipase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene a negative regulator of lipase activity? | CRISPR knockout in adipocytes or hepatocytes |
| Does a specific point mutation alter lipase inhibition? | Point-mutation knock-in cell lines [1,4] |
| How does a regulatory protein localize during lipolysis? | Tagged knock-in with fluorescent reporter |
| Does overexpression of a candidate gene suppress lipolysis? | Overexpression cell models |
| Which pathways mediate lysosomal stress effects on lipase activity? | TFEB knockout and overexpression models |
| Can a gene variant protect beta cells from lipotoxicity? | Beta-cell knockout and knock-in models |
How to Study the negative regulation of lipase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipase activity assay | Rate of lipid hydrolysis | Quantify negative regulation in edited cells [1,4] |
| Lipidomics | Lipid species abundance | Profile free fatty acids and triglycerides [1,2] |
| RNA-seq | Transcript abundance | Identify lipase gene expression changes |
| Proteomics | Protein abundance and modifications | Detect post-translational regulation |
| Fluorescence imaging | Lipid droplet and protein localization | Visualize lipase access to droplets |
| Autophagy flux assay | Lysosomal degradation activity | Assess TFEB pathway involvement |
| CRISPR screening | Gene function at scale | Discover novel negative regulators |
| Metabolomics | Small molecule profiles | Link diet to lipid metabolism |
Lipase activity assays
Enzymatic assays using triglyceride or phospholipid substrates measure the rate of hydrolysis and quantify negative regulation by candidate genes [1,4]. These assays are typically performed in lysates or live cells after CRISPR editing.
Lipidomics and metabolomics
Mass spectrometry-based lipidomics profiles free fatty acids, triglycerides and phospholipids to assess the impact of negative regulators on lipid flux [1,2]. Metabolomics can reveal diet-related changes in sebum and plasma lipids.
Transcriptomics and proteomics
RNA-seq and proteomics identify changes in lipase gene expression and protein abundance after knockout or overexpression of candidate regulators [1,6]. These methods help distinguish transcriptional from post-translational control.
Imaging and reporter assays
Fluorescent lipid droplet probes and tagged knock-in reporters visualize lipase localization and lipid droplet dynamics in live cells. Autophagy-lysosome reporters monitor TFEB pathway activation.
How CRISPR Can Be Used to Study GO:0060192 negative regulation of lipase activity
Knockout
CRISPR knockout of candidate genes such as PNPLA2, LIPE or PNPLA7 in adipocytes and hepatocytes tests whether loss of function increases lipase activity, confirming a negative regulatory role [1,6]. Knockout models are also used to study insulin signaling components like PDE3B.
Point Mutation
Point-mutation knock-in can mimic disease-associated variants or phospho-null mutations in regulators such as perilipin-1 or HSL, revealing how specific residues control lipase inhibition. These models are valuable for dissecting signaling-dependent regulation.
Knock-in
Tagged knock-in of genes like PNPLA7 or TFEB enables real-time tracking of protein localization and dynamics during lipolysis and lysosomal stress [3,6]. Reporter knock-ins can also monitor transcriptional responses.
Overexpression
Overexpression of candidate negative regulators, such as G0S2 or sphingomyelin-modifying enzymes, tests whether increased dosage suppresses lipase activity and protects against lipotoxicity [1,4]. Overexpression models complement loss-of-function studies.
How EDITGENE Supports negative regulation of lipase activity Research
Researchers studying negative regulation of lipase activity-related genes often need to determine whether a candidate gene is causally involved in suppressing lipid hydrolysis, and CRISPR-based models provide the most direct way to test this. EDITGENE offers a comprehensive suite of gene editing and screening services tailored to metabolic and lipase biology research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipase activity research.
Frequently Asked Questions About negative regulation of lipase activity
What is negative regulation of lipase activity (GO:0060192)?
It is a biological process that decreases the frequency, rate or extent of lipase activity, the hydrolysis of a lipid or phospholipid.
What genes are involved in negative regulation of lipase activity?
Key genes include PNPLA2, LIPE, MGLL, PNPLA7, LIPC, TFEB, PTGER4, PDE3B, G0S2 and PLIN1 [1,4,6,8].
How is lipase activity inhibited by insulin?
Insulin activates PDE3B, lowering cAMP and reducing PKA-dependent phosphorylation of HSL and perilipins, thereby suppressing lipolysis.
What role does sphingomyelin play in hepatic lipase regulation?
Sphingomyelin in plasma lipoproteins negatively regulates hepatic lipase activity, affecting lipoprotein remodeling.
How does PNPLA7 affect adipose tissue?
PNPLA7 mediates Parkin-mitochondrial recruitment for mitophagy and inhibits adipose browning.
Can CRISPR be used to study negative regulation of lipase activity?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models are widely used to test candidate regulators [1,6].
What diseases are linked to dysregulated lipase activity?
Obesity, insulin resistance, ectopic fat deposition, hepatic steatosis and acne have been linked to altered lipase regulation [1,2,8].
How does prostaglandin E2 affect lipolysis?
Prostaglandin E2 via the EP4 receptor promotes lipolysis and fibrosis in adipose tissue, leading to insulin resistance.
What is the role of TFEB in lipid metabolism?
TFEB is activated by lysosomal stress and coordinates autophagy-lysosome biogenesis, which intersects with lipid catabolism.
What methods measure negative regulation of lipase activity?
Lipase activity assays, lipidomics, RNA-seq, proteomics and imaging are commonly used [1,2,6].
Conclusion
GO:0060192, negative regulation of lipase activity, is a critical biological process that restrains lipid hydrolysis to maintain metabolic homeostasis. Its dysregulation contributes to obesity, insulin resistance, hepatic steatosis and other metabolic disorders [1,8]. Key regulators include insulin signaling components, sphingomyelin, PNPLA7, TFEB and prostaglandin E2-EP4 signaling [1,3,4,6,8]. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with lipidomics and transcriptomics, provide powerful tools to dissect these mechanisms and identify therapeutic targets.
References
- 1. Yang A et al.. 2020. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics.. Biochem J 477(5):985-1008 PMID: 32168372
- 2. Melnik BC. 2015. Linking diet to acne metabolomics, inflammation, and comedogenesis: an update.. Clin Cosmet Investig Dermatol 8:371-88 PMID: 26203267
- 3. Jeong SJ et al.. 2021. Trehalose causes low-grade lysosomal stress to activate TFEB and the autophagy-lysosome biogenesis response.. Autophagy 17(11):3740-3752 PMID: 33706671
- 4. Yang P et al.. 2015. Regulation of hepatic lipase activity by sphingomyelin in plasma lipoproteins.. Biochim Biophys Acta 1851(10):1327-36 PMID: 26193433
- 5. Blanc M et al.. 2024. Bax Inhibitor-1 preserves pancreatic β-cell proteostasis by limiting proinsulin misfolding and programmed cell death.. Cell Death Dis 15(5):334 PMID: 38744890
- 6. Ji X et al.. 2025. PNPLA7 mediates Parkin-mitochondrial recruitment in adipose tissue for mitophagy and inhibits browning.. Nat Commun 16(1):6651 PMID: 40681495
- 7. Rosenau F et al.. 2004. Lipase-specific foldases.. Chembiochem 5(2):152-61 PMID: 14760735
- 8. Inazumi T et al.. 2020. Prostaglandin E(2)-EP4 Axis Promotes Lipolysis and Fibrosis in Adipose Tissue Leading to Ectopic Fat Deposition and Insulin Resistance.. Cell Rep 33(2):108265 PMID: 33053354
